SCHEMBL29455255

SCHEMBL29455255

C=CCOC(=O)NCCN(CC(=O)NCCSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ HPGD P15428 1/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ AHCY P23526 1/20 0.34
▸ CKS1B P61024 1/20 0.34
▸ SKP1 P63208 1/20 0.34
▸ SKP2 Q13309 1/20 0.34
▸ CASP1 P29466 4/20 0.33
▸ KIF11 P52732 3/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ ADRB2 P07550 1/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ HDAC3 O15379 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC2 Q92769 1/20 0.31
▸ NCOR2 Q9Y618 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29455257 0.92 L3MBTL1 (0.36) L3MBTL1HPGDIDO1AHCYCKS1B
SCHEMBL13753391 0.82 KIF11 (0.43) HPGDKIF11
SCHEMBL30787947 0.78 SMN1; SMN2 (0.40) CASP1KIF11NPC1RAB9ASMN1; SMN2
SCHEMBL29455275 0.77 CASP1 (0.41) HPGDCASP1KIF11FAAH
SCHEMBL29455263 0.77 CASP1 (0.37) HPGDCASP1KIF11RAB9AHDAC3
SCHEMBL19265866 0.74 IDO1 (0.54) HPGDIDO1CKS1BSKP1SKP2
SCHEMBL13753316 0.74 KIF11 (0.43) HPGDKIF11
SCHEMBL9978229 0.74 KIF11 (0.36) HPGDIDO1KIF11HDAC3HDAC1
SCHEMBL29494628 0.73 SIRT2 (0.40) KIF11HDAC3HDAC1HDAC2NCOR2
SCHEMBL29494633 0.73 SIRT2 (0.40) KIF11HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE ASCENDIS PHARMA A/S (DK) 2025-04-24 — — US disclosed
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA GMBH (DE) 2024-02-08 — — US disclosed
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate ASCENDIS PHARMA A/S (DK) 2022-10-20 — — US disclosed
EP-3981761-A2 INTERMEDIATES FOR PRODRUGS Ascendis Pharma A/S (DK) 2022-04-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 L3MBTL1 68/4885HPGD 1998/4885IDO1 1896/4885
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate H1-0, H1-3, DLST L3MBTL1 65/4885HPGD 1728/4885IDO1 1505/4885
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE H1-0, H1-3, DLST L3MBTL1 65/4885HPGD 1728/4885IDO1 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback